GENinCode (LSE:GENI) Total Long-Term Assets : £0.82 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. GENinCode's Total Long-Term Assets for the quarter that ended in Jun. 2024 was £0.82 Mil.

GENinCode Total Long-Term Assets Historical Data

The historical data trend for GENinCode's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Total Long-Term Assets Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

0.10

0.15

0.24

1.31

0.99

GENinCode Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Long-Term Assets	Get a 7-Day Free Trial					0.37	1.31	1.15	0.99	0.82

GENinCode Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

GENinCode Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of GENinCode's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

9PL:Germany

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.